Functional Dyspepsia and Gastroparesis

Digestive Diseases

Volumn 34, Issue 5, 2016, Pages 491-499

  Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

Abdominal pain; Bloating; Nausea; Regurgitation; Rumination; Vomiting

Indexed keywords

ACOTIAMIDE; AMITRIPTYLINE; ANTIEMETIC AGENT; BUSPIRONE; CAMICINAL; GHRELIN; MIRTAZAPINE; PROKINETIC AGENT; RELAMORELIN; RELENOPRIDE; SEROTONIN 1A AGONIST; TANDOSPIRONE; TD 8954; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ARTICLE; BLOATING; DIABETES MELLITUS; DYSPEPSIA; ELECTROSTIMULATION; ERUCTATION; GASTROJEJUNOSTOMY; HUMAN; HYPERSENSITIVITY; IATROGENIC DISEASE; NAUSEA; NONHUMAN; POSTOPERATIVE ILEUS; PRIORITY JOURNAL; PYLOROPLASTY; RUMINATION; SCLERODERMA; STOMACH CONTENT; STOMACH EMPTYING; STOMACH OBSTRUCTION; STOMACH PARESIS; VOMITING; ADOLESCENT; ADULT; DIFFERENTIAL DIAGNOSIS; FEEDING AND EATING DISORDERS OF CHILDHOOD; FEMALE; GASTROPARESIS; MALE;

ADOLESCENT; ADULT; DIAGNOSIS, DIFFERENTIAL; DYSPEPSIA; FEEDING AND EATING DISORDERS OF CHILDHOOD; FEMALE; GASTROPARESIS; HUMANS; MALE;

EID: 84976330203     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000445226     Document Type: Article

References (60)

1. Vella A, Bock G, Giesler PD, Burton DB, Foley JE, Rizza RA, Camilleri M: Effect of a dipeptidyl peptidase 4 (DPP-4) inhibitor, vildagliptin, on gastrointestinal function, nutrient intake and glucose metabolism in type 2 diabetes. Neurogastroenterol Motil 2007; 19: 434.
2. Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL: The effects of sitagliptin on gastric emptying in healthy humans-A randomised, controlled study. Aliment Pharmacol Ther 2012; 36: 379-390.
3. Wu T, Ma J, Bound MJ, Checklin H, Deacon CF, Jones KL, Horowitz M, Rayner CK: Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. Diabetes 2014; 63: 2776-2787.
4. Maes BD, Vanwalleghem J, Kuypers D, Ghoos Y, Rutgeerts PJ, Vanrenterghem YF: Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. Transplantation 1999; 68: 1482-1485.
5. Maes BD, Evenepoel P, Kuypers D, Geypens B, Ghoos Y, Vanrenterghem Y: Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. Clin Transplant 2003; 17: 171-176.
6. Jeong ID, Camilleri M, Shin A, Iturrino J, Boldingh A, Busciglio I, Burton D, Ryks M, Rhoten D, Zinsmeister AR: A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans. Aliment Pharmacol Ther 2012; 35: 1088-1096.
7. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V: Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-1479.
8. Janssen P, Harris MS, Jones M, Masaoka T, Farré R, Törnblom H, Van Oudenhove L, Simrén M, Tack J: The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol 2013; 108: 1382-1391.
9. Tack J, Bisschops R, Sarnelli G: Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 1239-1255.
10. Corinaldesi R, Stanghellini V, Raiti C, Rea E, Salgemini R, Barbara L: Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987; 28: 300-305.
11. Jian R, Ducrot F, Ruskone A, Chaussade S, Rambaud JC, Modigliani R, Rain JD, Bernier JJ: Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci 1989; 34: 657-664.
12. Lembo A, Camilleri M, McCallum RW, Sastre RF, Breton CF, Spence SC, White J, Gottesdiener K, Stoner E: A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of RM-131 in patients with diabetic gastroparesis. Gastroenterology 2014; 146(suppl 1):S158-S159.
13. Kusunoki H, Haruma K, Manabe N, Imamura H, Kamada T, Shiotani A, Hata J, Sugioka H, Saito Y, Kato H, Tack J: Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by realtime ultrasonography. Neurogastroenterol Motil 2012; 24: 540-545, e250-e251.
14. Tack J, Janssen P, Masaoka T, Farré R, Van Oudenhove L: Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012; 10: 1239-1245.
15. Kolar GJ, Camilleri M, Burton D, Nadeau A, Zinsmeister AR: Prevalence of colonic motor or evacuation disorders in patients presenting with chronic nausea and vomiting evaluated by a single gastroenterologist in a tertiary referral practice. Neurogastroenterol Motil 2014; 26: 131-138.
16. Camilleri M, Shin A: Novel and validated approaches for gastric emptying scintigraphy in patients with suspected gastroparesis. Dig Dis Sci 2013; 58: 1813-1815.
17. Szarka LA, Camilleri M, Vella A, Burton D, Baxter K, Simonson J, Zinsmeister AR: A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol 2008; 6: 635-643.e1.
18. Camilleri M, Iturrino J, Bharucha AE, Burton D, Shin A, Jeong ID, Zinsmeister AR: Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants. Neurogastroenterol Motil 2012; 24: 1076-e562.
19. Odunsi ST, Camilleri M, Szarka LA, Zinsmeister AR: Optimizing analysis of stable isotope breath tests to estimate gastric emptying of solids. Neurogastroenterol Motil 2009; 21: 706-e38.
20. Bredenoord AJ, Chial HJ, Camilleri M, et al: Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003; 1: 264-272.
21. Bharucha AE, Camilleri M, Forstrom LA, Zinsmeister AR: Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol (Oxf) 2009; 70: 415-420.
22. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 1346-1352.
23. Bouras EP, Delgado-Aros S, Camilleri M, Castillo EJ, Burton DD, Thomforde GM, Chial HJ: SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 2002; 51: 781-786.
24. Tack J, Caenepeel P, Piessevaux H, Cuomo R, Janssens J: Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia. Gut 2003; 52: 1271-1277.
25. Sarnelli G, Vos R, Cuomo R, Janssens J, Tack J: Reproducibility of gastric barostat studies in healthy controls and in dyspeptic patients. Am J Gastroenterol 2001; 96: 1047-1053.
26. Breen M, Camilleri M, Burton D, Zinsmeister AR: Performance characteristics of the measurement of gastric volume using single photon emission computed tomography. Neurogastroenterol Motil 2011; 23: 308-315.
27. Janssen P, Verschueren S, Ly HG, Vos R, Van Oudenhove L, Tack J: Intragastric pressure during food intake: A physiological and minimally invasive method to assess gastric accommodation. Neurogastroenterol Motil 2011; 23: 316-322, e153-e154.
28. Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J: Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001; 121: 526-535.
29. Kumar A, Attaluri A, Hashmi S, Schulze KS, Rao SS: Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol Motil 2008; 20: 635-642.
30. Farré R, Vanheel H, Vanuytsel T, Masaoka T, Törnblom H, Simrén M, Van Oudenhove L, Tack JF: In functional dyspepsia, hypersensitivity to postprandial distention correlates with meal-related symptom severity. Gastroenterology 2013; 145: 566-573.
31. Bharucha AE, Camilleri M, Burton DD, Thieke SL, Feuerhak KJ, Basu A, Zinsmeister AR: Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia. Am J Gastroenterol 2014; 109: 1910-1920; quiz 1909, 1921.
32. O'Brien MD, Bruce BK, Camilleri M: The rumination syndrome: clinical features rather than manometric diagnosis. Gastroenterology 1995; 108: 1024-1029.
33. Chial HJ, Camilleri M, Williams DE, Litzinger K, Perrault J: Rumination syndrome in children and adolescents: diagnosis, treatment, and prognosis. Pediatrics 2003; 111: 158-162.
34. Wagaman JR, Williams DE, Camilleri M: Behavioral intervention for the treatment of rumination. J Pediatr Gastroenterol Nutr 1998; 27: 596-598.
35. Thumshirn M, Camilleri M, Hanson RB, Williams DE, Schei AJ, Kammer PP: Gastric mechanosensory and lower esophageal sphincter function in rumination syndrome. Am J Physiol 1998; 275(2 pt 1):G314-G321.
36. Vijayvargiya P, Iturrino J, Camilleri M, Shin A, Vazquez-Roque M, Katzka DA, Snuggerud JR, Seime RJ: Novel association of rectal evacuation disorder and rumination syndrome: diagnosis, co-morbidities and treatment. United European Gastroenterol J 2014; 2: 38-46.
37. Kim HS, Anderson JD, Saghafi O, Heard KJ, Monte AA: Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med 2015; 22: 694-699.
38. Allen JH, de Moore GM, Heddle R, Twartz JC: Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004; 53: 1566-1570.
39. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology: Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013; 108: 18-37; quiz 38.
40. Olausson EA, Störsrud S, Grundin H, Isaksson M, Attvall S, Simrén M: A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: A randomized controlled trial. Am J Gastroenterol 2014; 109: 375-385.
41. Sanger GJ, Westaway SM, Barnes AA, Macpherson DT, Muir AI, Jarvie EM, Bolton VN, Cellek S, Näslund E, Hellström PM, Borman RA, Unsworth WP, Matthews KL, Lee K: GSK962040: A small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil 2009; 21: 657-664, e30-e31.
42. Leming S, Broad J, Cozens SJ, Otterson M, Winchester W, Lee K, Dukes GE, Sanger GJ: GSK962040: A small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil 2011; 23: 958-e410.
43. Broad J, Mukherjee S, Samadi M, Martin JE, Dukes GE, Sanger GJ: Regional-and agonistdependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol 2012; 167: 763-774.
44. Camilleri M, Papathanasopoulos A, Odunsi ST: Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2009; 6: 343-352.
45. Van der Ploeg L, Laken H, Sharma S, Datta R, Halem H, Dong J, Touvay C, Teillot M, Noonan P, Tartaglia L, Stoner L, Henderson B, Gottesdiener K, Culler M: Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131. Life Sci 2014; 109: 20-29.
46. Shin A, Camilleri M, Busciglio I, Burton D, Stoner E, Noonan P, Gottesdiener K, Smith SA, Vella A, Zinsmeister AR: Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2013; 36: 41-48.
47. Shin A, Camilleri M, Busciglio I, Burton D, Smith SA, Vella A, Ryks M, Rhoten D, Zinsmeister AR: The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol 2013; 11: 1453-1459.e4.
48. Marek GJ, Carpenter LL, McDougle CJ, Price LH: Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 2003; 28: 402-412.
49. Yin J, Song J, Lei Y, Xu X, Chen JD: Prokinetic effects of mirtazapine on gastrointestinal transit. Am J Physiol Gastrointest Liver Physiol 2014; 306:G796-G801.
50. Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, Lacy BE, Müller-Lissner S, Quigley EM, Schuurkes J, De Maeyer JH, Stanghellini V: Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012; 35: 745-767.
51. Shin A, Acosta A, Camilleri M, Boldingh A, Burton D, Ryks M, Rhoten D, Zinsmeister AR: A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol 2015; 13: 701-708.e1.
52. McKinnell RM, Armstrong SR, Beattie DT, Fatheree PR, Long DD, Marquess DG, Shaw JP, Vickery RG: Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Bioorg Med Chem Lett 2013; 23: 4210-4215.
53. Beattie DT, Armstrong SR, Vickery RG, Tsuruda PR, Campbell CB, Richardson C, Mc-Cullough JL, Daniels O, Kersey K, Li YP, Kim KH: The pharmacology of TD-8954, a potent and selective 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Front Pharmacol 2011; 2: 25.
54. Chial HJ, Camilleri M, Burton D, Thomforde G, Olden KW, Stephens D: Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003; 284:G130-G137.
55. Van Oudenhove L, Kindt S, Vos R, Coulie B, Tack J: Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther 2008; 28: 1326-1333.
56. Tack J, Masclee A, Heading R, Berstad A, Piessevaux H, Popiela T, Vandenberghe A, Kato H: A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009; 21: 272-280.
57. Matsueda K, Hongo M, Tack J, Saito Y, Kato H: A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012; 61: 821-828.
58. Miwa H, Nagahara A, Tominaga K, Yokoyama T, Sawada Y, Inoue K, Ashida K, Fukuchi T, Hojo M, Yamashita H, Tomita T, Hori K, Oshima T: Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: A randomized controlled trial. Am J Gastroenterol 2009; 104: 2779-2787.
59. Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, Lacy BE, DiBaise JK, Prather CM, Abraham BP, El-Serag HB, Moayyedi P, Herrick LM, Szarka LA, Camilleri M, Hamilton FA, Schleck CD, Tilkes KE, Zinsmeister AR: Effect of amitriptyline and escitalopram on functional dyspepsia: A multicenter, randomized controlled study. Gastroenterology 2015; 149: 340-349.e2.
60. Camilleri M: Functional dyspepsia: mechanisms of symptom generation and appropriate management of patients. Gastroenterol Clin North Am 2007; 36: 649-664, xi-x.